Australian drug development company Biotron Limited (ASX:BIT) is set to announce a material capital raising.
The Australian Stock Exchange granted the company a trading halt pending the details, with its shares placed in pre-open.
Recently the company announced that all Hepatitis C virus (HCV) genotype 3 (G3) patients completing a key Phase 2 trial of its lead antiviral drug, BIT225, have undetectable levels of HCV 12 weeks after ceasing all treatment.
The company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.
The halt will remain in place until the opening of trade on Wednesday 15th October 2014, or earlier if an announcement is made to the market.
Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.
News: Biotron Limited to make material capital raising
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
